This site is intended for healthcare professionals only

In association with the Cardiorenal Forum

Articles

  • Polypharmacy in CKD: a reason to review, not withhold, cardiorenal protection

  • Canagliflozin and polypharmacy burden in CKD

  • Rituximab therapy compared to cyclophosphamide in ANCA-associated vasculitis

  • ASN Kidney health guidance on the cardiovascular-kidney-metabolic syndrome

  • ICU monitoring equipment and drip

    Dapagliflozin after cardiac surgery: reducing AKI or reducing the diagnosis of AKI?

  • Two surgeons during operation

    Dapagliflozin and acute kidney injury after cardiac surgery

  • Laboratory sample analyser

    Proteomic insights into dapagliflozin in CKD

  • Dialysis tubing next to bed

    The impact of haemodialysis on glycaemia

  • Gleaming stethoscope on laptop

    A FINE time to be a nephrologist

alt

For the latest news and articles
Sign up to Renal Review newsletters

Subscribe